Modeling arrhythmogenic right ventricular dysplasia/cardiomyopathy with patient-specific iPSCs

K. Shah, C. Y. Wei, C. S. Kim, J. Wong, J. Y. Wen, T. Tirasawasdichai, C. Wang, H. S. Vincent Chen

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Cellular reprogramming of somatic cells from cardiac patients to induced pluripotent stem cells (iPSCs) enables in vitro modeling of human genetic disorders for pathogenic investigations and therapeutic screens. However, using iPSC-derived cardiomyocytes (iPSC-CMs) to model an adult-onset heart disease remains challenging due to the uncertainty regarding the ability of relatively immature iPSC-CMs to fully recapitulate adult disease phenotypes. Arrhythmogenic right ventricular dysplasia (ARVD) is an inherited cardiomyopathy characterized by pathological fibrofatty infiltration and cardiomyocyte (CM) loss predominantly in the right ventricle (RV), leading to life-threatening ventricular arrhythmias. Over 50 % of affected individuals have desmosome gene mutations, most commonly in PKP2 encoding plakophilin-2. The median age at presentation of ARVD is 26-30 years. We used Yamanaka’s pluripotent factors to generate iPSC lines from two ARVD patients with PKP2 mutations. We first developed a method to induce metabolic maturation of iPSC-CMs and showed that induction of adult-like/fatty acid dominant energetics from an embryonic/glycolytic state is essential to model an adult-onset cardiac disease using patient-specific iPSC-CMs. Furthermore, we demonstrate that coactivation of normal peroxisome proliferator-activated receptor-alpha (PPARα) and abnormal PPARγ pathways led to aggressive lipogenesis, elevated apoptosis, and defective intracellular calcium handling in ARVD iPSC-CMs, recapitulating the pathological signatures of ARVD. PPAR? antagonists rescued all ARVD pathological phenotypes and reactive oxygen species (ROS) scavengers curtailed CM apoptosis in our ARVD in vitro model. Thus, using this model, we revealed novel pathogenic insights that metabolic derangement in an adult-like metabolic milieu underlies ARVD pathologies, enabling us to test novel disease-modifying therapeutic strategies.

Original languageEnglish (US)
Title of host publicationHuman iPS Cells in Disease Modelling
PublisherSpringer Japan
Pages27-43
Number of pages17
ISBN (Electronic)9784431559665
ISBN (Print)9784431559641
DOIs
StatePublished - Jan 1 2016
Externally publishedYes

Fingerprint

Arrhythmogenic Right Ventricular Dysplasia
Induced Pluripotent Stem Cells
Stem cells
PPAR alpha
Cardiac Myocytes
Plakophilins
Heart Diseases
Apoptosis
Phenotype
Desmosomes
Lipogenesis
Mutation
Inborn Genetic Diseases
Pathology
Infiltration
Medical Genetics
Cardiomyopathies
Reactive Oxygen Species
Uncertainty
Fatty Acids

Keywords

  • Fatty acid oxidation (FAO)
  • Induced pluripotent stem cell-derived cardiomyocytes
  • Metabolic maturation
  • Peroxisome proliferator-activated receptor (PPAR)
  • Reactive oxygen species (ROS)

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Shah, K., Wei, C. Y., Kim, C. S., Wong, J., Wen, J. Y., Tirasawasdichai, T., ... Vincent Chen, H. S. (2016). Modeling arrhythmogenic right ventricular dysplasia/cardiomyopathy with patient-specific iPSCs. In Human iPS Cells in Disease Modelling (pp. 27-43). Springer Japan. https://doi.org/10.1007/978-4-431-55966-5_3

Modeling arrhythmogenic right ventricular dysplasia/cardiomyopathy with patient-specific iPSCs. / Shah, K.; Wei, C. Y.; Kim, C. S.; Wong, J.; Wen, J. Y.; Tirasawasdichai, T.; Wang, C.; Vincent Chen, H. S.

Human iPS Cells in Disease Modelling. Springer Japan, 2016. p. 27-43.

Research output: Chapter in Book/Report/Conference proceedingChapter

Shah, K, Wei, CY, Kim, CS, Wong, J, Wen, JY, Tirasawasdichai, T, Wang, C & Vincent Chen, HS 2016, Modeling arrhythmogenic right ventricular dysplasia/cardiomyopathy with patient-specific iPSCs. in Human iPS Cells in Disease Modelling. Springer Japan, pp. 27-43. https://doi.org/10.1007/978-4-431-55966-5_3
Shah K, Wei CY, Kim CS, Wong J, Wen JY, Tirasawasdichai T et al. Modeling arrhythmogenic right ventricular dysplasia/cardiomyopathy with patient-specific iPSCs. In Human iPS Cells in Disease Modelling. Springer Japan. 2016. p. 27-43 https://doi.org/10.1007/978-4-431-55966-5_3
Shah, K. ; Wei, C. Y. ; Kim, C. S. ; Wong, J. ; Wen, J. Y. ; Tirasawasdichai, T. ; Wang, C. ; Vincent Chen, H. S. / Modeling arrhythmogenic right ventricular dysplasia/cardiomyopathy with patient-specific iPSCs. Human iPS Cells in Disease Modelling. Springer Japan, 2016. pp. 27-43
@inbook{4fa8b05da72f422c9fe416bc6d019858,
title = "Modeling arrhythmogenic right ventricular dysplasia/cardiomyopathy with patient-specific iPSCs",
abstract = "Cellular reprogramming of somatic cells from cardiac patients to induced pluripotent stem cells (iPSCs) enables in vitro modeling of human genetic disorders for pathogenic investigations and therapeutic screens. However, using iPSC-derived cardiomyocytes (iPSC-CMs) to model an adult-onset heart disease remains challenging due to the uncertainty regarding the ability of relatively immature iPSC-CMs to fully recapitulate adult disease phenotypes. Arrhythmogenic right ventricular dysplasia (ARVD) is an inherited cardiomyopathy characterized by pathological fibrofatty infiltration and cardiomyocyte (CM) loss predominantly in the right ventricle (RV), leading to life-threatening ventricular arrhythmias. Over 50 {\%} of affected individuals have desmosome gene mutations, most commonly in PKP2 encoding plakophilin-2. The median age at presentation of ARVD is 26-30 years. We used Yamanaka’s pluripotent factors to generate iPSC lines from two ARVD patients with PKP2 mutations. We first developed a method to induce metabolic maturation of iPSC-CMs and showed that induction of adult-like/fatty acid dominant energetics from an embryonic/glycolytic state is essential to model an adult-onset cardiac disease using patient-specific iPSC-CMs. Furthermore, we demonstrate that coactivation of normal peroxisome proliferator-activated receptor-alpha (PPARα) and abnormal PPARγ pathways led to aggressive lipogenesis, elevated apoptosis, and defective intracellular calcium handling in ARVD iPSC-CMs, recapitulating the pathological signatures of ARVD. PPAR? antagonists rescued all ARVD pathological phenotypes and reactive oxygen species (ROS) scavengers curtailed CM apoptosis in our ARVD in vitro model. Thus, using this model, we revealed novel pathogenic insights that metabolic derangement in an adult-like metabolic milieu underlies ARVD pathologies, enabling us to test novel disease-modifying therapeutic strategies.",
keywords = "Fatty acid oxidation (FAO), Induced pluripotent stem cell-derived cardiomyocytes, Metabolic maturation, Peroxisome proliferator-activated receptor (PPAR), Reactive oxygen species (ROS)",
author = "K. Shah and Wei, {C. Y.} and Kim, {C. S.} and J. Wong and Wen, {J. Y.} and T. Tirasawasdichai and C. Wang and {Vincent Chen}, {H. S.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/978-4-431-55966-5_3",
language = "English (US)",
isbn = "9784431559641",
pages = "27--43",
booktitle = "Human iPS Cells in Disease Modelling",
publisher = "Springer Japan",
address = "Japan",

}

TY - CHAP

T1 - Modeling arrhythmogenic right ventricular dysplasia/cardiomyopathy with patient-specific iPSCs

AU - Shah, K.

AU - Wei, C. Y.

AU - Kim, C. S.

AU - Wong, J.

AU - Wen, J. Y.

AU - Tirasawasdichai, T.

AU - Wang, C.

AU - Vincent Chen, H. S.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Cellular reprogramming of somatic cells from cardiac patients to induced pluripotent stem cells (iPSCs) enables in vitro modeling of human genetic disorders for pathogenic investigations and therapeutic screens. However, using iPSC-derived cardiomyocytes (iPSC-CMs) to model an adult-onset heart disease remains challenging due to the uncertainty regarding the ability of relatively immature iPSC-CMs to fully recapitulate adult disease phenotypes. Arrhythmogenic right ventricular dysplasia (ARVD) is an inherited cardiomyopathy characterized by pathological fibrofatty infiltration and cardiomyocyte (CM) loss predominantly in the right ventricle (RV), leading to life-threatening ventricular arrhythmias. Over 50 % of affected individuals have desmosome gene mutations, most commonly in PKP2 encoding plakophilin-2. The median age at presentation of ARVD is 26-30 years. We used Yamanaka’s pluripotent factors to generate iPSC lines from two ARVD patients with PKP2 mutations. We first developed a method to induce metabolic maturation of iPSC-CMs and showed that induction of adult-like/fatty acid dominant energetics from an embryonic/glycolytic state is essential to model an adult-onset cardiac disease using patient-specific iPSC-CMs. Furthermore, we demonstrate that coactivation of normal peroxisome proliferator-activated receptor-alpha (PPARα) and abnormal PPARγ pathways led to aggressive lipogenesis, elevated apoptosis, and defective intracellular calcium handling in ARVD iPSC-CMs, recapitulating the pathological signatures of ARVD. PPAR? antagonists rescued all ARVD pathological phenotypes and reactive oxygen species (ROS) scavengers curtailed CM apoptosis in our ARVD in vitro model. Thus, using this model, we revealed novel pathogenic insights that metabolic derangement in an adult-like metabolic milieu underlies ARVD pathologies, enabling us to test novel disease-modifying therapeutic strategies.

AB - Cellular reprogramming of somatic cells from cardiac patients to induced pluripotent stem cells (iPSCs) enables in vitro modeling of human genetic disorders for pathogenic investigations and therapeutic screens. However, using iPSC-derived cardiomyocytes (iPSC-CMs) to model an adult-onset heart disease remains challenging due to the uncertainty regarding the ability of relatively immature iPSC-CMs to fully recapitulate adult disease phenotypes. Arrhythmogenic right ventricular dysplasia (ARVD) is an inherited cardiomyopathy characterized by pathological fibrofatty infiltration and cardiomyocyte (CM) loss predominantly in the right ventricle (RV), leading to life-threatening ventricular arrhythmias. Over 50 % of affected individuals have desmosome gene mutations, most commonly in PKP2 encoding plakophilin-2. The median age at presentation of ARVD is 26-30 years. We used Yamanaka’s pluripotent factors to generate iPSC lines from two ARVD patients with PKP2 mutations. We first developed a method to induce metabolic maturation of iPSC-CMs and showed that induction of adult-like/fatty acid dominant energetics from an embryonic/glycolytic state is essential to model an adult-onset cardiac disease using patient-specific iPSC-CMs. Furthermore, we demonstrate that coactivation of normal peroxisome proliferator-activated receptor-alpha (PPARα) and abnormal PPARγ pathways led to aggressive lipogenesis, elevated apoptosis, and defective intracellular calcium handling in ARVD iPSC-CMs, recapitulating the pathological signatures of ARVD. PPAR? antagonists rescued all ARVD pathological phenotypes and reactive oxygen species (ROS) scavengers curtailed CM apoptosis in our ARVD in vitro model. Thus, using this model, we revealed novel pathogenic insights that metabolic derangement in an adult-like metabolic milieu underlies ARVD pathologies, enabling us to test novel disease-modifying therapeutic strategies.

KW - Fatty acid oxidation (FAO)

KW - Induced pluripotent stem cell-derived cardiomyocytes

KW - Metabolic maturation

KW - Peroxisome proliferator-activated receptor (PPAR)

KW - Reactive oxygen species (ROS)

UR - http://www.scopus.com/inward/record.url?scp=84978250410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978250410&partnerID=8YFLogxK

U2 - 10.1007/978-4-431-55966-5_3

DO - 10.1007/978-4-431-55966-5_3

M3 - Chapter

AN - SCOPUS:84978250410

SN - 9784431559641

SP - 27

EP - 43

BT - Human iPS Cells in Disease Modelling

PB - Springer Japan

ER -